Indian Policy Shifts Could Force Firms To Abandon 'Second Brand' Strategies
India’s new draft pharmaceutical policy proposes a raft of radical changes that have left industry jittery and could force a significant realignment in the operations of foreign and local firms. Second brand strategies and widespread licensing-out of manufacturing are no longer favored, and a 'one company – one drug – one brand name – one price' thrust are among the key changes proposed.
You may also be interested in...
In honor of its former secretary-general DG Shah, the Indian Pharmaceutical Alliance has created a public policy award at the Indian Institute of Management in Ahmedabad.
The Indian Pharmaceutical Alliance, which has been at the forefront in representing the interests of the country’s large domestic generic drugmakers, has appointed industry veteran Sudarshan Jain as its new secretary general, replacing founder Dilip Shah who died in February.
Generics industry veteran and secretary general of the Indian Pharmaceutical Alliance, Dilip Shah, has died aged 77. Shah played a pivotal role in ensuring that the Indian generics industry’s voice was heard.